Anixa Biosciences Capital Expenditures (CapEx) Growth & History (ANIX)
Anixa Biosciences's capital expenditures (capex) was $15,791 for fiscal 2020.
View full Anixa Biosciences company overviewAnixa Biosciences annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2020 | 2020-10-31 | $15,791 | −$159,666 | −91.00% |
| 2019 | 2019-10-31 | $175,457 | $137,053 | +356.87% |
| 2018 | 2018-10-31 | $38,404 | $8,216 | +27.22% |
| 2017 | 2017-10-31 | $30,188 | −$116,333 | −79.40% |
| 2016 | 2016-10-31 | $146,521 | $91,745 | +167.49% |
| 2015 | 2015-10-31 | $54,776 | $48,092 | +719.51% |
| 2014 | 2014-10-31 | $6,684 | — | — |
| 2012 | 2012-10-31 | $1,600 | −$7,428 | −82.28% |
| 2011 | 2011-10-31 | $9,028 | $6,959 | +336.35% |
| 2010 | 2010-10-31 | $2,069 | — | — |
Anixa Biosciences quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2020 | 2020-10-31 | $0 | — | — |
| Q3 2020 | 2020-07-31 | $0 | $0 | — |
| Q2 2020 | 2020-04-30 | $1 | — | — |
| Q1 2020 | 2020-01-31 | $15,790 | — | — |
| Q3 2019 | 2019-07-31 | $0 | −$20,040 | — |
| Q4 2018 | 2018-10-31 | $6,551 | −$6,752 | −50.76% |
| Q3 2018 | 2018-07-31 | $20,040 | $17,276 | +625.04% |
| Q2 2018 | 2018-04-30 | $9,295 | $9,295 | — |
| Q1 2018 | 2018-01-31 | $2,518 | −$11,603 | −82.17% |
| Q4 2017 | 2017-10-31 | $13,303 | $11,432 | +611.01% |
| Q3 2017 | 2017-07-31 | $2,764 | −$776 | −21.92% |
| Q2 2017 | 2017-04-30 | $0 | −$35,098 | — |
| Q1 2017 | 2017-01-31 | $14,121 | −$91,891 | −86.68% |
| Q4 2016 | 2016-10-31 | $1,871 | $1,871 | — |
| Q3 2016 | 2016-07-31 | $3,540 | $3,540 | — |
| Q2 2016 | 2016-04-30 | $35,098 | $35,098 | — |
| Q1 2016 | 2016-01-31 | $106,012 | $51,236 | +93.54% |
| Q4 2015 | 2015-10-31 | $0 | −$6.1M | — |
| Q3 2015 | 2015-07-31 | $0 | $0 | — |
| Q2 2015 | 2015-04-30 | $0 | −$3.0M | — |
| Q1 2015 | 2015-01-31 | $54,776 | −$3.0M | −98.20% |
| Q4 2014 | 2014-10-31 | $6.1M | — | — |
| Q3 2014 | 2014-07-31 | $0 | −$1,097 | — |
| Q2 2014 | 2014-04-30 | $3.0M | $3.0M | +173286.64% |
| Q1 2014 | 2014-01-31 | $3.0M | $3.0M | +123064.30% |
| Q3 2013 | 2013-07-31 | $1,097 | $1,097 | — |
| Q2 2013 | 2013-04-30 | $1,751 | $1,001 | +133.47% |
| Q1 2013 | 2013-01-31 | $2,465 | $1,615 | +190.00% |
| Q4 2012 | 2012-10-31 | $0 | $0 | — |
| Q3 2012 | 2012-07-31 | $0 | −$575 | — |
| Q2 2012 | 2012-04-30 | $750 | −$1,457 | −66.02% |
| Q1 2012 | 2012-01-31 | $850 | −$5,396 | −86.39% |
| Q4 2011 | 2011-10-31 | $0 | — | — |
| Q3 2011 | 2011-07-31 | $575 | — | — |
| Q2 2011 | 2011-04-30 | $2,207 | — | — |
| Q1 2011 | 2011-01-31 | $6,246 | — | — |
Anixa Biosciences capital expenditures (capex) trends
Over the last five fiscal years, Anixa Biosciences's capital expenditures (capex) decreased from $54,776 to $15,791, a change of −$38,985. The latest reported quarter, Q4 2020, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anixa Biosciences source filings ↗